Gilead locks in Daniel O'­Day as CEO, tap­ping the Roche vet to re­ju­ve­nate growth

The sus­pense over who will suc­ceed John Mil­li­gan at Gilead has fi­nal­ly end­ed.

Daniel O’Day, cur­rent CEO of Roche’s Phar­ma di­vi­sion, has been tapped for the top job, Gilead an­nounced days be­fore Mil­li­gan is set to de­part from his cor­ner of­fice.

John Mil­li­gan

O’Day’s ap­point­ment ush­ers in a new era for the Fos­ter City, CA-based big biotech, which Mil­li­gan and his pre­de­ces­sor, John Mar­tin, ran for near­ly three decades, cre­at­ing an HIV pow­er­house and an in­dus­try-dom­i­nat­ing he­pati­tis C fran­chise. In re­cent years, how­ev­er, it’s seen its rev­enue shrink as com­pe­ti­tion heats up and the pain­less cure ef­fec­tive­ly down­sized the mar­ket.

Mar­tin has pre­vi­ous­ly an­nounced his de­par­ture as board chair­man, amid an ex­ec­u­tive ex­o­dus that al­so claimed R&D head Nor­bert Bischoberg­er, CMO An­drew Cheng and com­mer­cial chief James Mey­ers (who is re­tir­ing).

Be­fore O’Day as­sumes his role on March 1, 2019, Gregg Al­ton — a 20-year vet­er­an of the com­pa­ny who’s served as gen­er­al coun­sel and, most re­cent­ly, chief pa­tient of­fi­cer — will man the fort as in­ter­im CEO.

In­vestors wel­comed the news, send­ing Gilead shares $GILD up 2.5%.

O’Day, who Jef­feries’ Michael Yee de­scribes as “pret­ty straight down the road” in terms of risk tak­ing with­out a his­to­ry of big M&A deal­ing, grad­u­ates from Roche as a 30-year vet­er­an of the Swiss phar­ma gi­ant, hav­ing start­ed with com­mer­cial and sales roles in 1987. Since tak­ing con­trol of the phar­ma unit in 2012, he’s over­seen the launch of sev­er­al po­ten­tial block­buster drugs in­clud­ing Hem­li­bra and Tecen­triq.

Baird’s Bri­an Sko­r­ney, mean­while, of­fers a de­cid­ed­ly glow­ing re­view of the new CEO:

(I)n his role at Roche, we think he has done a phe­nom­e­nal job at nav­i­gat­ing the com­pa­ny in­to a next gen­er­a­tion of prod­ucts (Ocre­vus, Hem­li­bra, po­latuzum­ab are just a cou­ple of prod­ucts we see as new, im­pact­ful block­buster drugs). Most im­por­tant­ly, we be­lieve the long his­to­ry at Roche makes him a choice that isn’t like­ly to break an al­ready good com­pa­ny. While we ex­pect that re­plac­ing the head of one of the strongest man­age­ment teams ever seen in biotech to be a chal­leng­ing role, we think that O’Day is high­ly qual­i­fied and should ease in­vestor con­cerns lead­ing in­to Mil­li­gan’s re­tire­ment.

While in­vestors keen­ly await a strate­gic plan and vi­sion from O’Day, an­a­lysts at Jef­feries laid out a pos­si­ble sce­nario:

We be­lieve O’Day will look to de­vel­op a strat­e­gy over the course of 2019 and it will in­clude a view on de­ploy­ing GILD’s cur­rent cash of ~$32B to­wards more on­col­o­gy as­sets and oth­er key ar­eas, such as in­flam­ma­tion and liv­er dis­eases. Note’s GILD’s cur­rent debt-to-EBIT­DA ra­tio stands at rough­ly ~2.6x so the com­pa­ny could still lever up to do more deals. (…) we can as­sume his plan-of-ac­tion for 2019 is to en­sure that: (1) HCV sta­bi­lizes and be­comes more “pre­dictable”, (2) HIV grows as Bik­tarvy con­tin­ues to reach record rev­enues, and (3) Yescar­ta grows each quar­ter as the com­pa­ny con­tin­ues to ex­pand its pres­ence in hema­tol­ogy (e.g. al­lo­gene­ic CAR-T) and sol­id tu­mors (neo-anti­gens).

Faced with a wan­ing hep C fran­chise, Gilead has swal­lowed Kite Phar­ma in a bid to be­come a leader in CAR-T, snap­ping up new tech­nolo­gies along the way. It is now up to O’Day to gal­va­nize the sales of Kite’s CAR-T ther­a­py Yescar­ta, which de­spite im­pres­sive sur­vival rates gen­er­at­ed a pal­try $183 mil­lion for the first nine months of 2018.

Mean­while in Basel, Genen­tech CEO Bill An­der­son will fill O’Day’s shoes.


Im­age: Daniel O’Day. ROCHE

Teresa Graham, incoming Roche Pharmaceuticals CEO

In­com­ing Roche CEO builds out his top team, tap­ping Genen­tech vet to lead phar­ma di­vi­sion

Roche announced another leadership shuffle Thursday morning – the head of global product strategy, Teresa Graham, will take over as CEO of Roche Pharmaceuticals in March while the company’s corporate executive committee will make a spot for Levi Garraway, CMO and executive VP of global product development.

Thomas Schinecker will take over the top spot as Roche group CEO in March, leaving his spot as head of diagnostics.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

John Roberts, exiting Vyant Bio CEO

Neu­rode­gen­er­a­tive biotech Vyant warns of po­ten­tial wind-down

The CEO and chief scientific officer of Vyant Bio are out the door as the little-known but publicly-listed neurodegenerative biotech searches for an exit or, if all else fails, a wind-down.

The soul-searching bookends a winding journey for the biotech, which rebranded and transitioned from diagnostics company Cancer Genetics in 2021 after a merger with StemoniX. That came after a failed merger attempt with NovellusDx (now Fore Biotherapeutics) in 2018. In the last few years, units have been sold off and the stock price $VYNT has plummeted from the $30 range to penny stock territory.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Medicago's vaccine greenhouse (Medicago via YouTube)

Cana­di­an plant-based vac­cine de­vel­op­er Med­ica­go shut­ters months af­ter lay­offs

Plant-based Covid-19 vaccine developer Medicago shut down this week with little fanfare. And its two subsidiaries, Medicago R&D and Medicago USA, are also closing their doors, according to a company news release.

The lone shareholder left standing, Japan-based Mitsubishi Chemical Group, “has determined not to make further investments in Medicago and to proceed with an orderly wind-up of its business and operations in Canada and in the United States.”

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.